Crossmark

Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

Crossref DOI link: https://doi.org/10.1007/s00262-021-03108-x

Published Online: 2021-11-28

Published Print: 2022-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bureau, Mathilde

Chatellier, Thierry

Perennec, Tanguy

Goronflot, Thomas

Greilsamer, Charlotte

Chene, Anne-Laure

Affi, Raafet

Frampas, Eric

Bennouna, Jaafar

Pons-Tostivint, Elvire https://orcid.org/0000-0003-4478-0523
License Information

Text and Data Mining valid from 2021-11-28

Version of Record valid from 2021-11-28
More Information

Article History

Received: 17 July 2021

Accepted: 5 November 2021

First Online: 28 November 2021

Declarations

:

: The authors declare that they do not have any conflict of interest.

: In accordance with local regulations.

Document is current

Any future updates will be listed below